Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1993;2(1):3–21. doi: 10.1155/S0962935193000018

Biological significance of soluble IL-2 receptor

Calogero Caruso 1,✉, Giuseppina Candore 1, Diego Cigna 1, Antonio Tobia Colucci 1, Maria Assunta Modica 1
PMCID: PMC2365387  PMID: 18475497

Abstract

A NUMBER of receptors for growth factors and differentiation antigens have been found to be secreted or released by cells. Following mononuclear cell (MNC) activation and interleukin-2 receptor (IL-2R) expression, a soluble form of the Alpha;-chain of IL-2R (sIL-2R) is released. The sIL-2R has been shown to be present in the culture supernatants of activated MNCs as well as in normal sera and, in higher amounts, in sera from subjects affected by several diseases including neoplastic, infectious and autoimmune ones, and in sera from transplanted patients suffering allograft rejection. The blood sIL-2R levels depend on the number of producing cells and the number of molecules per cell, so that sIL-2R blood values may represent an index of the number and the functional state of producing cells, both normal and neoplastic. Thus, monitoring of the immune system, mostly T-cells and haematological malignancies might be targets for the measurement of sIL-2R. Since many conditions may influence sIL-2R production, little diagnostic use may result from these measurements. However, since blood sIL-2R levels may correlate with disease progression and/or response to therapy, their measurement may be a useful index of activity and extent of disease. The precise biological role of the soluble form of the IL-2R is still a matter of debate. However, we know that increased sIL-2R levels may be observed in association with several immunological abnormalities and that sIL-2R is able to bind IL-2. It is conceivable then that in these conditions the excess sIL-2R released in vivo by activated lymphoid cells or by neoplastic cells may somehow regulate IL-2-dependent processes. On the other hand, it cannot exclude that sIL-2R is a by-product without biological significance. Finally, it is puzzling that in many conditions in which an increase of blood sIL-2R values has been observed, MNCs display a decreased in vitro capacity to produce sIL-2R. These seemingly contrasting findings are discussed in the light of the data showing that sIL-2R production correlates with IL-2 production.

Full Text

The Full Text of this article is available as a PDF (2.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Zeid Y. A., Theander T. G., Abdulhadi N. H., Hviid L., Saeed B. O., Jepsen S., Jensen J. B., Bayoumi R. A. Modulation of the cellular immune response during Plasmodium falciparum infections in sickle cell trait individuals. Clin Exp Immunol. 1992 Apr;88(1):112–118. doi: 10.1111/j.1365-2249.1992.tb03048.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Activation antigens and signal transduction in lymphocyte activation. Immunol Rev. 1987 Feb;95:1–194. [PubMed] [Google Scholar]
  3. Adams D. H., Wang L., Hubscher S. G., Elias E., Neuberger J. M. Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet. 1989 Mar 4;1(8636):469–471. doi: 10.1016/s0140-6736(89)91368-8. [DOI] [PubMed] [Google Scholar]
  4. Balazs C., Farid N. R. Soluble interleukin-2 receptor in sera of patients with Graves' disease. J Autoimmun. 1991 Aug;4(4):681–688. doi: 10.1016/0896-8411(91)90185-f. [DOI] [PubMed] [Google Scholar]
  5. Bansil S., Troiano R., Cook S. D., Rohowsky-Kochan C. Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis. Acta Neurol Scand. 1991 Oct;84(4):282–285. doi: 10.1111/j.1600-0404.1991.tb04955.x. [DOI] [PubMed] [Google Scholar]
  6. Brahams D. Brain damage due to blocked tracheostomy tube: a 12-year saga. Lancet. 1989 Jan 7;1(8628):55–55. doi: 10.1016/s0140-6736(89)91718-2. [DOI] [PubMed] [Google Scholar]
  7. Bresson-Hadni S., Monnot-Jacquard B., Racadot E., Lenys D., Miguet J. P., Vuitton D. A. Soluble IL-2-receptor and CD8 in the serum and the periparasitic granuloma of patients with alveolar echinococcosis. Eur Cytokine Netw. 1991 Nov-Dec;2(5):339–344. [PubMed] [Google Scholar]
  8. Brown A. E., Rieder K. T., Webster H. K. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis. 1989 Apr;139(4):1036–1038. doi: 10.1164/ajrccm/139.4.1036. [DOI] [PubMed] [Google Scholar]
  9. Brynskov J., Tvede N., Andersen C. B., Vilien M. Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut. 1992 Jan;33(1):55–58. doi: 10.1136/gut.33.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Campen D. H., Horwitz D. A., Quismorio F. P., Jr, Ehresmann G. R., Martin W. J. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 1988 Nov;31(11):1358–1364. doi: 10.1002/art.1780311103. [DOI] [PubMed] [Google Scholar]
  11. Candore G., Di Lorenzo G., Caruso C., Modica M. A., Colucci A. T., Crescimanno G., Ingrassia A., Sangiorgi G. B., Salerno A. The effect of age on mitogen responsive T cell precursors in human beings is completely restored by interleukin-2. Mech Ageing Dev. 1992 May;63(3):297–307. doi: 10.1016/0047-6374(92)90007-z. [DOI] [PubMed] [Google Scholar]
  12. Caruso C., Di Lorenzo G., Modica M. A., Candore G., Portelli M. R., Crescimanno G., Ingrassia A., Sangiorgi G. B., Salerno A. Soluble interleukin-2 receptor release defect in vitro in elderly subjects. Mech Ageing Dev. 1991 Jun 14;59(1-2):27–35. doi: 10.1016/0047-6374(91)90071-7. [DOI] [PubMed] [Google Scholar]
  13. Caruso C., Modica M. A., Candore G., Di Giulio C., Galluzzo A., Giordano C., Di Marco P., Gebbia V., Tamone Reyes M., Citarrella P. Soluble interleukin-2 receptor in vitro production by mononuclear cells from Hodgkin patients. Boll Ist Sieroter Milan. 1990;69(1):335–338. [PubMed] [Google Scholar]
  14. Chilosi M., Semenzato G., Cetto G., Ambrosetti A., Fiore-Donati L., Perona G., Berton G., Lestani M., Scarpa A., Agostini C. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood. 1987 Nov;70(5):1530–1535. [PubMed] [Google Scholar]
  15. Chu C. M., Liaw Y. F. Serum levels of soluble Tac peptide in acute and chronic hepatitis B virus infection. Clin Immunol Immunopathol. 1989 Oct;53(1):52–58. doi: 10.1016/0090-1229(89)90100-1. [DOI] [PubMed] [Google Scholar]
  16. Cohen-Kaminsky S., Jacques Y., Aime C., Safar D., Morel E., Berrih-Aknin S. Follow-up of soluble interleukin-2 receptor levels after thymectomy in patients with myasthenia gravis. Clin Immunol Immunopathol. 1992 Feb;62(2):190–198. doi: 10.1016/0090-1229(92)90072-v. [DOI] [PubMed] [Google Scholar]
  17. Colvin R. B., Fuller T. C., MacKeen L., Kung P. C., Ip S. H., Cosimi A. B. Plasma interleukin 2 receptor levels in renal allograft recipients. Clin Immunol Immunopathol. 1987 May;43(2):273–276. doi: 10.1016/0090-1229(87)90135-8. [DOI] [PubMed] [Google Scholar]
  18. Colvin R. B., Preffer F. I., Fuller T. C., Brown M. C., Ip S. H., Kung P. C., Cosimi A. B. A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Transplantation. 1989 Nov;48(5):800–805. doi: 10.1097/00007890-198911000-00015. [DOI] [PubMed] [Google Scholar]
  19. Cosman D., Cerretti D. P., Larsen A., Park L., March C., Dower S., Gillis S., Urdal D. Cloning, sequence and expression of human interleukin-2 receptor. Nature. 1984 Dec 20;312(5996):768–771. doi: 10.1038/312768a0. [DOI] [PubMed] [Google Scholar]
  20. Crabtree J. E., Heatley R. V., Juby L. D., Howdle P. D., Losowsky M. S. Serum interleukin-2-receptor in coeliac disease: response to treatment and gluten challenge. Clin Exp Immunol. 1989 Sep;77(3):345–348. [PMC free article] [PubMed] [Google Scholar]
  21. Degiannis D., Seibold J. R., Czarnecki M., Raskova J., Raska K., Jr Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Arthritis Rheum. 1990 Mar;33(3):375–380. doi: 10.1002/art.1780330310. [DOI] [PubMed] [Google Scholar]
  22. Deloron P., Lepers J. P., Coulanges P. Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria. J Clin Microbiol. 1989 Aug;27(8):1887–1889. doi: 10.1128/jcm.27.8.1887-1889.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dummer R., Posseckert G., Nestle F., Witzgall R., Burger M., Becker J. C., Schäfer E., Wiede J., Sebald W., Burg G. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo? J Invest Dermatol. 1992 Jan;98(1):50–54. doi: 10.1111/1523-1747.ep12494223. [DOI] [PubMed] [Google Scholar]
  24. Fahey J. L., Taylor J. M., Detels R., Hofmann B., Melmed R., Nishanian P., Giorgi J. V. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990 Jan 18;322(3):166–172. doi: 10.1056/NEJM199001183220305. [DOI] [PubMed] [Google Scholar]
  25. Famularo G., Procopio A., Giacomelli R., Danese C., Sacchetti S., Perego M. A., Santoni A., Tonietti G. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol. 1990 Sep;81(3):368–372. doi: 10.1111/j.1365-2249.1990.tb05340.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Filley E., Andreoli A., Steele J., Waters M., Wagner D., Nelson D., Tung K., Rademacher T., Dwek R., Rook G. A. A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodosum leprosum. Clin Exp Immunol. 1989 Jun;76(3):343–347. [PMC free article] [PubMed] [Google Scholar]
  27. Foa R., Giovarelli M., Jemma C., Fierro M. T., Lusso P., Ferrando M. L., Lauria F., Forni G. Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population. Blood. 1985 Sep;66(3):614–619. [PubMed] [Google Scholar]
  28. Forsythe J. L., Shenton B. K., Parrot N. R., Taylor R. M., Proud G. Plasma interleukin 2 receptor levels in renal allograft dysfunction. Transplantation. 1989 Jul;48(1):155–157. doi: 10.1097/00007890-198907000-00039. [DOI] [PubMed] [Google Scholar]
  29. Galli M., Ridolfo A. L., Balotta C., Riva A., Cocchi F., Musicco M., Albarello V., Moroni M. Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine. AIDS. 1991 Oct;5(10):1231–1235. doi: 10.1097/00002030-199110000-00012. [DOI] [PubMed] [Google Scholar]
  30. Giannitsis D. J., Müller-Hof B., Häcker-Shahin B. Serum soluble interleukin-2 receptor levels of normal blood donors. Cytobios. 1991;68(274-275):161–164. [PubMed] [Google Scholar]
  31. Gilmore S. J., Benson E. M., Kelly J. W. Serum interleukin-2 receptor levels and cutaneous T-cell lymphoma. Australas J Dermatol. 1991;32(2):101–105. doi: 10.1111/j.1440-0960.1991.tb00074.x. [DOI] [PubMed] [Google Scholar]
  32. Giordano C., Galluzzo A., Marco A., Pantò F., Amato M. P., Caruso C., Bompiani G. D. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res. 1988 Jul;8(3):135–138. [PubMed] [Google Scholar]
  33. Giordano C., Pantò F., Caruso C., Modica M. A., Zambito A. M., Sapienza N., Amato M. P., Galluzzo A. Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes. 1989 Mar;38(3):310–315. doi: 10.2337/diab.38.3.310. [DOI] [PubMed] [Google Scholar]
  34. Greenberg S. J., Marcon L., Hurwitz B. J., Waldmann T. A., Nelson D. L. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med. 1988 Oct 13;319(15):1019–1020. doi: 10.1056/NEJM198810133191517. [DOI] [PubMed] [Google Scholar]
  35. Greene W. C., Leonard W. J., Depper J. M., Nelson D. L., Waldmann T. A. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. Ann Intern Med. 1986 Oct;105(4):560–572. doi: 10.7326/0003-4819-105-4-560. [DOI] [PubMed] [Google Scholar]
  36. Greene W. C., Leonard W. J. The human interleukin-2 receptor. Annu Rev Immunol. 1986;4:69–95. doi: 10.1146/annurev.iy.04.040186.000441. [DOI] [PubMed] [Google Scholar]
  37. Greene W. C. The human interleukin-2 receptor: a molecular and biochemical analysis of structure and function. Clin Res. 1987 Sep;35(5):439–450. [PubMed] [Google Scholar]
  38. Griffin D. E., Ward B. J., Jauregui E., Johnson R. T., Vaisberg A. Immune activation in measles. N Engl J Med. 1989 Jun 22;320(25):1667–1672. doi: 10.1056/NEJM198906223202506. [DOI] [PubMed] [Google Scholar]
  39. Harrington D. S., Patil K., Lai P. K., Yasuda N. N., Armitage J. O., Ip S. H., Weisenburger D. D., Linder J., Purtilo D. T. Soluble interleukin 2 receptors in patients with malignant lymphoma. Arch Pathol Lab Med. 1988 Jun;112(6):597–601. [PubMed] [Google Scholar]
  40. Hatakeyama M., Kono T., Kobayashi N., Kawahara A., Levin S. D., Perlmutter R. M., Taniguchi T. Interaction of the IL-2 receptor with the src-family kinase p56lck: identification of novel intermolecular association. Science. 1991 Jun 14;252(5012):1523–1528. doi: 10.1126/science.2047859. [DOI] [PubMed] [Google Scholar]
  41. Hatakeyama M., Tsudo M., Minamoto S., Kono T., Doi T., Miyata T., Miyasaka M., Taniguchi T. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science. 1989 May 5;244(4904):551–556. doi: 10.1126/science.2785715. [DOI] [PubMed] [Google Scholar]
  42. Herrmann F., Cannistra S. A., Levine H., Griffin J. D. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med. 1985 Sep 1;162(3):1111–1116. doi: 10.1084/jem.162.3.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Hofmann B., Bass H., Nishanian P., Faisal M., Figlin R. A., Sarna G. P., Fahey J. L. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha. Clin Exp Immunol. 1992 Jun;88(3):548–554. doi: 10.1111/j.1365-2249.1992.tb06485.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Hofmann B., Nishanian P., Fahey J. L., Esmail I., Jackson A. L., Detels R., Cumberland W. Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: distinctive parameters of HIV-induced change. Clin Immunol Immunopathol. 1991 Nov;61(2 Pt 1):212–224. doi: 10.1016/s0090-1229(05)80025-x. [DOI] [PubMed] [Google Scholar]
  45. Holter W., Goldman C. K., Casabo L., Nelson D. L., Greene W. C., Waldmann T. A. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol. 1987 May 1;138(9):2917–2922. [PubMed] [Google Scholar]
  46. Hsu M. M., Ko J. Y., Chang Y. L. Elevated levels of soluble interleukin 2 receptor and tumor necrosis factor in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1991 Nov;117(11):1257–1259. doi: 10.1001/archotol.1991.01870230073010. [DOI] [PubMed] [Google Scholar]
  47. Hsu S. M., Yang K., Jaffe E. S. Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease. Am J Pathol. 1985 Feb;118(2):209–217. [PMC free article] [PubMed] [Google Scholar]
  48. Huang Y. P., Perrin L. H., Miescher P. A., Zubler R. H. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol. 1988 Aug 1;141(3):827–833. [PubMed] [Google Scholar]
  49. Hänninen E. L., Körfer A., Hadam M., Schneekloth C., Dallmann I., Menzel T., Kirchner H., Poliwoda H., Atzpodien J. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res. 1991 Dec 1;51(23 Pt 1):6312–6316. [PubMed] [Google Scholar]
  50. Imagawa D. T., Lee M. H., Wolinsky S. M., Sano K., Morales F., Kwok S., Sninsky J. J., Nishanian P. G., Giorgi J., Fahey J. L. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med. 1989 Jun 1;320(22):1458–1462. doi: 10.1056/NEJM198906013202205. [DOI] [PubMed] [Google Scholar]
  51. Jung L. K., Hara T., Fu S. M. Detection and functional studies of p60-65 (Tac antigen) on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1597–1602. doi: 10.1084/jem.160.5.1597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Jutte N. H., Hesse C. J., Balk A. H., Mochtar B., Weimar W. Sequential measurements of soluble interleukin 2 receptor levels in plasma of heart transplant recipients. Transplantation. 1990 Aug;50(2):328–330. [PubMed] [Google Scholar]
  53. Kapp A., Neuner P., Krutmann J., Luger T. A., Schöpf E. Production of interleukin-2 by mononuclear cells in vitro in patients with atopic dermatitis and psoriasis. Comparison with serum interleukin-2 receptor levels. Acta Derm Venereol. 1991;71(5):403–406. [PubMed] [Google Scholar]
  54. Kay N. E., Burton J., Wagner D., Nelson D. L. The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. Blood. 1988 Aug;72(2):447–450. [PubMed] [Google Scholar]
  55. Keystone E. C., Snow K. M., Bombardier C., Chang C. H., Nelson D. L., Rubin L. A. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum. 1988 Jul;31(7):844–849. doi: 10.1002/art.1780310704. [DOI] [PubMed] [Google Scholar]
  56. Kloster B. E., John P. A., Miller L. E., Rubin L. A., Nelson D. L., Blair D. C., Tomar R. H. Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol. 1987 Dec;45(3):440–446. doi: 10.1016/0090-1229(87)90095-x. [DOI] [PubMed] [Google Scholar]
  57. Kniep E. M., Strelow I., Lohmann-Matthes M. L. The monocyte interleukin-2 receptor light chain: production of cell-associated and soluble interleukin-2 receptor by monocytes. Immunology. 1992 Feb;75(2):299–304. [PMC free article] [PubMed] [Google Scholar]
  58. Komp D. M., Shapiro E., McNamara J. Soluble interleukin-2 receptor in childhood non-Hodgkin's lymphoma. Blood. 1988 Apr;71(4):1172–1174. [PubMed] [Google Scholar]
  59. Korsmeyer S. J., Greene W. C., Cossman J., Hsu S. M., Jensen J. P., Neckers L. M., Marshall S. L., Bakhshi A., Depper J. M., Leonard W. J. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4522–4526. doi: 10.1073/pnas.80.14.4522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Kroemer G., Andreu J. L., Gonzalo J. A., Gutierrez-Ramos J. C., Martínez C. Interleukin-2, autotolerance, and autoimmunity. Adv Immunol. 1991;50:147–235. doi: 10.1016/s0065-2776(08)60825-1. [DOI] [PubMed] [Google Scholar]
  61. Lai K. N., Leung J. C., Chow C. C., Cockram C. S. T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production. Acta Endocrinol (Copenh) 1989 May;120(5):602–609. doi: 10.1530/acta.0.1200602. [DOI] [PubMed] [Google Scholar]
  62. Lai K. N., Leung J. C., Lai F. M. Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro. Pathology. 1991 Jul;23(3):224–228. doi: 10.3109/00313029109063570. [DOI] [PubMed] [Google Scholar]
  63. Lang B. A., Silverman E. D., Laxer R. M., Rose V., Nelson D. L., Rubin L. A. Serum-soluble interleukin-2 receptor levels in Kawasaki disease. J Pediatr. 1990 Apr;116(4):592–596. doi: 10.1016/s0022-3476(05)81610-5. [DOI] [PubMed] [Google Scholar]
  64. Lemmer B., Schwuléra U., Thrun A., Lissner R. Circadian rhythm of soluble interleukin-2 receptor in healthy individuals. Eur Cytokine Netw. 1992 May-Jun;3(3):335–336. [PubMed] [Google Scholar]
  65. Leonard W. J., Depper J. M., Crabtree G. R., Rudikoff S., Pumphrey J., Robb R. J., Krönke M., Svetlik P. B., Peffer N. J., Waldmann T. A. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature. 1984 Oct 18;311(5987):626–631. doi: 10.1038/311626a0. [DOI] [PubMed] [Google Scholar]
  66. Leonard W. J., Depper J. M., Robb R. J., Waldmann T. A., Greene W. C. Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6957–6961. doi: 10.1073/pnas.80.22.6957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Leung N. W., Leung J. C., Tam J. S., Lau J. T., Lai K. N. Effects of alpha-interferon and prednisone on serum-soluble interleukin-2 receptor (sIL-2R) in chronic hepatitis B infection. Am J Gastroenterol. 1992 Jan;87(1):113–117. [PubMed] [Google Scholar]
  68. Lissoni P., Barni S., Rovelli F., Viviani S., Maestroni G. J., Conti A., Tancini G. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer. 1990 Jan;26(1):33–36. doi: 10.1016/0277-5379(90)90253-p. [DOI] [PubMed] [Google Scholar]
  69. Lotze M. T., Custer M. C., Sharrow S. O., Rubin L. A., Nelson D. L., Rosenberg S. A. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res. 1987 Apr 15;47(8):2188–2195. [PubMed] [Google Scholar]
  70. Lovett D. H., Ryan J. L., Sterzel R. B. A thymocyte-activating factor derived from glomerular mesangial cells. J Immunol. 1983 Apr;130(4):1796–1801. [PubMed] [Google Scholar]
  71. Manoussakis M. N., Papadopoulos G. K., Drosos A. A., Moutsopoulos H. M. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol. 1989 Mar;50(3):321–332. doi: 10.1016/0090-1229(89)90140-2. [DOI] [PubMed] [Google Scholar]
  72. Manoussakis M. N., Stavropoulos E. D., Germanidis G. S., Papasteriades C. A., Garalea K. L., Dontas A. S., Moutsopoulos H. M. Soluble interleukin-2 receptors and autoantibodies in the serum of healthy elderly individuals. Autoimmunity. 1990;7(2-3):129–137. doi: 10.3109/08916939008993385. [DOI] [PubMed] [Google Scholar]
  73. Marcon L., Rubin L. A., Kurman C. C., Fritz M. E., Longo D. L., Uchiyama T., Edwards B. K., Nelson D. L. Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: correlation with clinical status during chemotherapy. Ann Intern Med. 1988 Aug 15;109(4):274–279. doi: 10.7326/0003-4819-109-4-274. [DOI] [PubMed] [Google Scholar]
  74. Marino P., Cugno M., Preatoni A., Cori P., Rosti A., Frontini L., Cicardi M. Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer. Br J Cancer. 1990 Mar;61(3):434–435. doi: 10.1038/bjc.1990.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Mariotti S., Caturegli P., Barbesino G., Del Prete G. F., Chiovato L., Pinchera A. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism. J Endocrinol Invest. 1991 Oct;14(9):777–781. doi: 10.1007/BF03347915. [DOI] [PubMed] [Google Scholar]
  76. Matsumoto T., Miike T., Yamaguchi K., Murakami M., Kawabe T., Yodoi J. Serum levels of soluble IL-2 receptor, IL-4 and IgE-binding factors in childhood allergic diseases. Clin Exp Immunol. 1991 Aug;85(2):288–292. doi: 10.1111/j.1365-2249.1991.tb05720.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Matsuoka M., Hattori T., Kawano F., Ishii T., Uchiyama T., Takatsuki K. Expression of Tac antigen on human immature B-cell lineage leukemic cells. Leuk Res. 1986;10(6):597–603. doi: 10.1016/0145-2126(86)90261-4. [DOI] [PubMed] [Google Scholar]
  78. Matsuura T., West G. A., Klein J. S., Ferraris L., Fiocchi C. Soluble interleukin 2 and CD8 and CD4 receptors in inflammatory bowel disease. Gastroenterology. 1992 Jun;102(6):2006–2014. doi: 10.1016/0016-5085(92)90326-t. [DOI] [PubMed] [Google Scholar]
  79. Miyajima A., Kitamura T., Harada N., Yokota T., Arai K. Cytokine receptors and signal transduction. Annu Rev Immunol. 1992;10:295–331. doi: 10.1146/annurev.iy.10.040192.001455. [DOI] [PubMed] [Google Scholar]
  80. Modica M. A., Zambito A. M., Candore G., Caruso C. Markers of T lymphocyte activation in HLA-B8, DR3 positive individuals. Immunobiology. 1990 Nov;181(4-5):257–266. doi: 10.1016/S0171-2985(11)80517-6. [DOI] [PubMed] [Google Scholar]
  81. Modica M. A., di Lorenzo G., Galluzzo A., Giordano C., Portelli M. R., Candore G., Caruso C. Soluble interleukin-2 receptor secretion defect in vitro in HLA-B8, DR3 positive subjects. Autoimmunity. 1990;7(2-3):87–96. doi: 10.3109/08916939008993381. [DOI] [PubMed] [Google Scholar]
  82. Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007–1008. doi: 10.1126/science.181845. [DOI] [PubMed] [Google Scholar]
  83. Morishima Y., Morishita Y., Adachi K., Tanimoto M., Ohno R., Saito H. Phorbol ester induces interleukin-2 receptor on the cell surface of precursor thymocyte leukemia with no rearrangement of T cell receptor beta and gamma genes. Blood. 1987 Nov;70(5):1291–1296. [PubMed] [Google Scholar]
  84. Mosmann T. R., Coffman R. L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol. 1989;46:111–147. doi: 10.1016/s0065-2776(08)60652-5. [DOI] [PubMed] [Google Scholar]
  85. Mosmann T. R., Coffman R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi: 10.1146/annurev.iy.07.040189.001045. [DOI] [PubMed] [Google Scholar]
  86. Motoi T., Uchiyama T., Hori T., Itoh K., Uchino H., Ueda R. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood. 1989 Aug 15;74(3):1052–1057. [PubMed] [Google Scholar]
  87. Murashima A., Takasaki Y., Ohgaki M., Hashimoto H., Shirai T., Hirose S. Activated peripheral blood mononuclear cells detected by murine monoclonal antibodies to proliferating cell nuclear antigen in active lupus patients. J Clin Immunol. 1990 Jan;10(1):28–37. doi: 10.1007/BF00917495. [DOI] [PubMed] [Google Scholar]
  88. Nelson D. L., Kurman C. C., Fritz M. E., Boutin B., Rubin L. A. The production of soluble and cellular interleukin-2 receptors by cord blood mononuclear cells following in vitro activation. Pediatr Res. 1986 Feb;20(2):136–139. doi: 10.1203/00006450-198602000-00008. [DOI] [PubMed] [Google Scholar]
  89. Nielsen H., Nielsen H. J., Tvede N., Klarlund K., Mansa B., Moesgaard F., Drivsholm A. Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. APMIS. 1991 Apr;99(4):340–346. doi: 10.1111/j.1699-0463.1991.tb05159.x. [DOI] [PubMed] [Google Scholar]
  90. Nikaido T., Shimizu A., Ishida N., Sabe H., Teshigawara K., Maeda M., Uchiyama T., Yodoi J., Honjo T. Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature. 1984 Oct 18;311(5987):631–635. doi: 10.1038/311631a0. [DOI] [PubMed] [Google Scholar]
  91. Noronha I. L., Daniel V., Schimpf K., Opelz G. Soluble IL-2 receptor and tumour necrosis factor-alpha in plasma of haemophilia patients infected with HIV. Clin Exp Immunol. 1992 Feb;87(2):287–292. doi: 10.1111/j.1365-2249.1992.tb02989.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. North M. E., Spickett G. P., Webster A. D., Farrant J. Raised serum levels of CD8, CD25 and beta 2-microglobulin in common variable immunodeficiency. Clin Exp Immunol. 1991 Nov;86(2):252–255. doi: 10.1111/j.1365-2249.1991.tb05805.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Parera M., Rivera F., Egido J., Campos A. The role of interleukin 2 (IL-2) and serum-soluble IL-2 receptor cells in idiopathic IgA nephropathy. Clin Immunol Immunopathol. 1992 May;63(2):196–199. doi: 10.1016/0090-1229(92)90013-e. [DOI] [PubMed] [Google Scholar]
  94. Perkins J. D., Nelson D. L., Rakela J., Grambsch P. M., Krom R. A. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation. 1989 Jan;47(1):77–81. doi: 10.1097/00007890-198901000-00018. [DOI] [PubMed] [Google Scholar]
  95. Perkins J. D., Nelson D. L., Rakela J., Grambsch P. M., Krom R. A. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation. 1989 Jan;47(1):77–81. doi: 10.1097/00007890-198901000-00018. [DOI] [PubMed] [Google Scholar]
  96. Pizzolo G., Chilosi M., Semenzato G., Caligaris-Cappio F., Fiore-Donati L., Perona G., Janossy G. Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease. Br J Cancer. 1984 Sep;50(3):415–417. doi: 10.1038/bjc.1984.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Pizzolo G., Chilosi M., Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br J Haematol. 1987 Dec;67(4):377–380. doi: 10.1111/j.1365-2141.1987.tb06156.x. [DOI] [PubMed] [Google Scholar]
  98. Pizzolo G., Chilosi M., Vinante F., Dazzi F., Lestani M., Perona G., Benedetti F., Todeschini G., Vincenzi C., Trentin L. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer. 1987 Apr;55(4):427–428. doi: 10.1038/bjc.1987.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Poulakis N., Sarandakou A., Rizos D., Phocas I., Kontozoglou T., Polyzogopoulos D. Soluble interleukin-2 receptors and other markers in primary lung cancer. Cancer. 1991 Sep 1;68(5):1045–1049. doi: 10.1002/1097-0142(19910901)68:5<1045::aid-cncr2820680523>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  100. Proujansky R., Carpenter A. B. Soluble interleukin-2 receptor as a marker of lymphocyte activation in childhood Crohn's disease. J Pediatr Gastroenterol Nutr. 1991 Oct;13(3):277–284. doi: 10.1097/00005176-199110000-00007. [DOI] [PubMed] [Google Scholar]
  101. Pui C. H., Ip S. H., Iflah S., Behm F. G., Grose B. H., Dodge R. K., Crist W. M., Furman W. L., Murphy S. B., Rivera G. K. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood. 1988 Apr;71(4):1135–1137. [PubMed] [Google Scholar]
  102. Pui C. H., Ip S. H., Kung P., Dodge R. K., Berard C. W., Crist W. M., Murphy S. B. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood. 1987 Sep;70(3):624–628. [PubMed] [Google Scholar]
  103. Pui C. H. Serum interleukin-2 receptor: clinical and biological implications. Leukemia. 1989 May;3(5):323–327. [PubMed] [Google Scholar]
  104. Raziuddin S., al-Janadi M. A., al-Wabel A. A. Soluble interleukin 2 receptor levels in serum and its relationship to T cell abnormality and clinical manifestations of the disease in patients with systemic lupus erythematosus. J Rheumatol. 1991 Jun;18(6):831–836. [PubMed] [Google Scholar]
  105. Robb R. J., Greene W. C. Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor. J Exp Med. 1987 Apr 1;165(4):1201–1206. doi: 10.1084/jem.165.4.1201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Robb R. J., Rusk C. M., Yodoi J., Greene W. C. Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2002–2006. doi: 10.1073/pnas.84.7.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res. 1991;21(2):152–158. doi: 10.1007/BF02591635. [DOI] [PubMed] [Google Scholar]
  108. Rubin L. A., Kurman C. C., Biddison W. E., Goldman N. D., Nelson D. L. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma. 1985 Summer;4(2):91–102. doi: 10.1089/hyb.1985.4.91. [DOI] [PubMed] [Google Scholar]
  109. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  110. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  111. Rubin L. A., Snow K. M., Kurman C. C., Nelson D. L., Keystone E. C. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol. 1990 May;17(5):597–602. [PubMed] [Google Scholar]
  112. Schreiber S., Raedler A., Conn A. R., Rombeau J. L., MacDermott R. P. Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease. Gut. 1992 Feb;33(2):236–241. doi: 10.1136/gut.33.2.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Schroeder T. J., Helling T., McKenna R. M., Rush D., Jeffrey J. R., Brewer B., Martin L. A., Traylor D., Fisher R. A., First M. R. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients. Transplantation. 1992 Jan;53(1):34–40. [PubMed] [Google Scholar]
  114. Semenzato G., Cipriani A., Trentin L., Zambello R., Masciarelli M., Vinante F., Chilosi M., Pizzolo G. High serum levels of soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis. 1987 Mar;4(1):25–27. [PubMed] [Google Scholar]
  115. Semenzato G., Foa R., Agostini C., Zambello R., Trentin L., Vinante F., Benedetti F., Chilosi M., Pizzolo G. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood. 1987 Aug;70(2):396–400. [PubMed] [Google Scholar]
  116. Sethi K. K., Näher H. Elevated titers of cell-free interleukin-2 receptor in serum and cerebrospinal fluid specimens of patients with acquired immunodeficiency syndrome. Immunol Lett. 1986 Oct;13(4):179–184. doi: 10.1016/0165-2478(86)90052-0. [DOI] [PubMed] [Google Scholar]
  117. Sheibani K., Winberg C. D., van de Velde S., Blayney D. W., Rappaport H. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. Am J Pathol. 1987 Apr;127(1):27–37. [PMC free article] [PubMed] [Google Scholar]
  118. Siegel J. P., Sharon M., Smith P. L., Leonard W. J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science. 1987 Oct 2;238(4823):75–78. doi: 10.1126/science.3116668. [DOI] [PubMed] [Google Scholar]
  119. Silverman E. D., Laxer R. M., Nelson D. L., Rubin L. A. Soluble interleukin-2 receptor in juvenile rheumatoid arthritis. J Rheumatol. 1991 Sep;18(9):1398–1402. [PubMed] [Google Scholar]
  120. Simmonds P., Beatson D., Cuthbert R. J., Watson H., Reynolds B., Peutherer J. F., Parry J. V., Ludlam C. A., Steel C. M. Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet. 1991 Nov 9;338(8776):1159–1163. doi: 10.1016/0140-6736(91)92029-2. [DOI] [PubMed] [Google Scholar]
  121. Smith K. A. Interleukin 2. Annu Rev Immunol. 1984;2:319–333. doi: 10.1146/annurev.iy.02.040184.001535. [DOI] [PubMed] [Google Scholar]
  122. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  123. Steis R. G., Marcon L., Clark J., Urba W., Longo D. L., Nelson D. L., Maluish A. E. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood. 1988 May;71(5):1304–1309. [PubMed] [Google Scholar]
  124. Strauchen J. A., Breakstone B. A. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol. 1987 Mar;126(3):506–512. [PMC free article] [PubMed] [Google Scholar]
  125. Symons J. A., McCulloch J. F., Wood N. C., Duff G. W. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol. 1991 Jul;60(1):72–82. doi: 10.1016/0090-1229(91)90113-o. [DOI] [PubMed] [Google Scholar]
  126. Symons J. A., Wood N. C., Di Giovine F. S., Duff G. W. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol. 1988 Oct 15;141(8):2612–2618. [PubMed] [Google Scholar]
  127. Symons J. A., Wood N. C., di Giovine F. S., Duff G. W. Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol. 1990 Jun;80(3):354–359. doi: 10.1111/j.1365-2249.1990.tb03292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Taga K., Kasahara Y., Yachie A., Miyawaki T., Taniguchi N. Preferential expression of IL-2 receptor subunits on memory populations within CD4+ and CD8+ T cells. Immunology. 1991 Jan;72(1):15–19. [PMC free article] [PubMed] [Google Scholar]
  129. Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., Munakata H., Nakamura M., Sugamura K. Cloning of the gamma chain of the human IL-2 receptor. Science. 1992 Jul 17;257(5068):379–382. doi: 10.1126/science.1631559. [DOI] [PubMed] [Google Scholar]
  130. Tamura K., Nagamine N., Araki Y., Seita M., Okayama A., Kawano K., Tachibana N., Tsuda K., Kuroki Y., Narita H. Clinical analysis of 33 patients with adult T-cell leukemia (ATL)-diagnostic criteria and significance of high- and low-risk ATL. Int J Cancer. 1986 Mar 15;37(3):335–341. doi: 10.1002/ijc.2910370303. [DOI] [PubMed] [Google Scholar]
  131. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24;302(5906):305–310. doi: 10.1038/302305a0. [DOI] [PubMed] [Google Scholar]
  132. Teodorczyk-Injeyan J. A., Sparkes B. G., Mills G. B., Falk R. E., Peters W. J. Increase of serum interleukin 2 receptor level in thermally injured patients. Clin Immunol Immunopathol. 1989 May;51(2):205–215. doi: 10.1016/0090-1229(89)90020-2. [DOI] [PubMed] [Google Scholar]
  133. Teodorczyk-Injeyan J. A., Sparkes B. G., Mills G. B., Peters W. J. Soluble interleukin 2-receptor alpha secretion is related to altered interleukin 2 production in thermally injured patients. Burns. 1991 Aug;17(4):290–295. doi: 10.1016/0305-4179(91)90042-f. [DOI] [PubMed] [Google Scholar]
  134. Teshigawara K., Wang H. M., Kato K., Smith K. A. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med. 1987 Jan 1;165(1):223–238. doi: 10.1084/jem.165.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Tisi E., Lissoni P., Angeli M., Arrigoni C., Corno E., Cassina E., Ballabio D., Benenti C., Barni S., Tancini G. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer. 1992 May 15;69(10):2458–2462. doi: 10.1002/1097-0142(19920515)69:10<2458::aid-cncr2820691013>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  136. Tokano Y., Murashima A., Takasaki Y., Hashimoto H., Okumura K., Hirose S. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis. 1989 Oct;48(10):803–809. doi: 10.1136/ard.48.10.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Tomkinson B. E., Wagner D. K., Nelson D. L., Sullivan J. L. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987 Dec 1;139(11):3802–3807. [PubMed] [Google Scholar]
  138. Touw I., Delwel R., Bolhuis R., van Zanen G., Löwenberg B. Common and pre-B acute lymphoblastic leukemia cells express interleukin 2 receptors, and interleukin 2 stimulates in vitro colony formation. Blood. 1985 Sep;66(3):556–561. [PubMed] [Google Scholar]
  139. Trotter J. L., Clifford D. B., Anderson C. B., van der Veen R. C., Hicks B. C., Banks G. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis. N Engl J Med. 1988 May 5;318(18):1206–1206. doi: 10.1056/nejm198805053181816. [DOI] [PubMed] [Google Scholar]
  140. Tung K. S., Umland E., Matzner P., Nelson K., Schauf V., Rubin L., Wagner D., Scollard D., Vithayasai P., Vithayasai V. Soluble serum interleukin 2 receptor levels in leprosy patients. Clin Exp Immunol. 1987 Jul;69(1):10–15. [PMC free article] [PubMed] [Google Scholar]
  141. Ullman K. S., Northrop J. P., Verweij C. L., Crabtree G. R. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol. 1990;8:421–452. doi: 10.1146/annurev.iy.08.040190.002225. [DOI] [PubMed] [Google Scholar]
  142. Visani G., Delwel R., Touw I., Bot F., Löwenberg B. Membrane receptors for interleukin 2 on hematopoietic precursors in chronic myeloid leukemia. Blood. 1987 Apr;69(4):1182–1187. [PubMed] [Google Scholar]
  143. Vitale G., Reina G., Mansueto S., Malta R., Gambino G., Mocciaro C., D'Agostino R., Dieli M., Cillari E. The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients. Clin Exp Immunol. 1992 Nov;90(2):219–222. doi: 10.1111/j.1365-2249.1992.tb07932.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Wagner F., Assemi C., Lersch C., Hart R., Classen M. Soluble interleukin-2 receptor and soluble CD8 in liver cirrhosis and obstructive jaundice. Clin Exp Immunol. 1990 Nov;82(2):344–349. doi: 10.1111/j.1365-2249.1990.tb05450.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Waldmann T. A., Goldman C. K., Robb R. J., Depper J. M., Leonard W. J., Sharrow S. O., Bongiovanni K. F., Korsmeyer S. J., Greene W. C. Expression of interleukin 2 receptors on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1450–1466. doi: 10.1084/jem.160.5.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Waldmann T. A., Greene W. C., Sarin P. S., Saxinger C., Blayney D. W., Blattner W. A., Goldman C. K., Bongiovanni K., Sharrow S., Depper J. M. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest. 1984 Jun;73(6):1711–1718. doi: 10.1172/JCI111379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Waldmann T. A. The interleukin-2 receptor. J Biol Chem. 1991 Feb 15;266(5):2681–2684. [PubMed] [Google Scholar]
  148. Waldmann T. A. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 1986 May 9;232(4751):727–732. doi: 10.1126/science.3008337. [DOI] [PubMed] [Google Scholar]
  149. Wang H. M., Smith K. A. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med. 1987 Oct 1;166(4):1055–1069. doi: 10.1084/jem.166.4.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Ward M. M., Dooley M. A., Christenson V. D., Pisetsky D. S. The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus. J Rheumatol. 1991 Feb;18(2):235–240. [PubMed] [Google Scholar]
  151. Ward M. M., Hall R. P., Pisetsky D. S. Serum interleukin-2 receptor responses to immunization. Clin Immunol Immunopathol. 1990 Oct;57(1):120–124. doi: 10.1016/0090-1229(90)90027-n. [DOI] [PubMed] [Google Scholar]
  152. Williams A. J., Symons J. A., Watchet K., Duff G. W. Soluble interleukin-2 receptor and disease activity in Crohn's disease. J Autoimmun. 1992 Apr;5(2):251–259. doi: 10.1016/0896-8411(92)90204-4. [DOI] [PubMed] [Google Scholar]
  153. Wolf R. E., Brelsford W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988 Jun;31(6):729–735. doi: 10.1002/art.1780310605. [DOI] [PubMed] [Google Scholar]
  154. Wong K. L., Wong R. P. Serum soluble interleukin 2 receptor in systemic lupus erythematosus: effects of disease activity and infection. Ann Rheum Dis. 1991 Oct;50(10):706–709. doi: 10.1136/ard.50.10.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Wood N. C., Symons J. A., Duff G. W. Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun. 1988 Aug;1(4):353–361. doi: 10.1016/0896-8411(88)90005-4. [DOI] [PubMed] [Google Scholar]
  156. Wörmann B., Anderson J. M., Ling Z. D., LeBien T. W. Structure/function analyses of IL-2 binding proteins on human B cell precursor acute lymphoblastic leukemias. Leukemia. 1987 Sep;1(9):660–666. [PubMed] [Google Scholar]
  157. Yamaguchi S., Onji M., Ohta Y. Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases. Hepatogastroenterology. 1988 Oct;35(5):245–248. [PubMed] [Google Scholar]
  158. Yasuda N., Lai P. K., Ip S. H., Kung P. C., Hinuma Y., Matsuoka M., Hattori T., Takatsuki K., Purtilo D. T. Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood. 1988 Apr;71(4):1021–1026. [PubMed] [Google Scholar]
  159. Yodoi J., Uchiyama T. Diseases associated with HTLV-I: virus, IL-2 receptor dysregulation and redox regulation. Immunol Today. 1992 Oct;13(10):405–411. doi: 10.1016/0167-5699(92)90091-K. [DOI] [PubMed] [Google Scholar]
  160. Young J. B., Windsor N. T., Smart F. W., Kleiman N. S., Weilbaecher D. G., Noon G. P., Nelson D. L., Lawrence E. C. Inability of isolated soluble interleukin-2 receptor levels to predict biopsy rejection scores after heart transplantation. Transplantation. 1991 Mar;51(3):636–641. doi: 10.1097/00007890-199103000-00018. [DOI] [PubMed] [Google Scholar]
  161. Zachariae C., Larsen C. S., Kaltoft K., Deleuran B., Larsen C. G., Thestrup-Pedersen K. Soluble IL2 receptor serum levels and epidermal cytokines in mycosis fungoides and related disorders. Acta Derm Venereol. 1991;71(6):465–470. [PubMed] [Google Scholar]
  162. Zerler B. The soluble interleukin-2 receptor as a marker for human neoplasia and immune status. Cancer Cells. 1991 Dec;3(12):471–479. [PubMed] [Google Scholar]
  163. Zielinski C. C., Müller C., Tichatschek E., Aiginger P. Decreased production of soluble interleukin 2 receptor by phytohaemagglutinin-stimulated peripheral blood mononuclear cells in patients with breast cancer after adjuvant therapy. Br J Cancer. 1989 Nov;60(5):712–714. doi: 10.1038/bjc.1989.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Zielinski C. C., Pesau B., Müller C. Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritis. Clin Immunol Immunopathol. 1990 Oct;57(1):74–82. doi: 10.1016/0090-1229(90)90023-j. [DOI] [PubMed] [Google Scholar]
  165. Zwierzina H., Herold M., Schöllenberger S., Geissler D., Schmalzl F. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF. Br J Haematol. 1991 Nov;79(3):438–443. doi: 10.1111/j.1365-2141.1991.tb08052.x. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES